Lung cancer is often diagnosed at an advanced stage, when treatment options are limited. Chest X-ray remains the most widely used imaging examination worldwide — and a critical opportunity for earlier detection, provided that subtle signs are recognized in time.
In January 2025, Bristol Myers Squibb and Carebot launched a pilot program across nine Czech hospitals (including two University centers), integrating AI-powered chest X-ray analysis directly into routine workflows. In its first six months, the system analyzed over 100,000 examinations, flagging potential abnormalities for rapid multidisciplinary review and fast track diagnostic follow-up.
Data after 3-months will be shown together with the most interesting case reports where AI-support clearly demonstrated its added value for identification of early stages of lung cancer where benefit of possible subsequent therapies seems to be the most significant.